Navigation Links
Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
Date:3/31/2009

Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen's Anemia Business. Throughout his 20 years at Amgen, Narachi held various positions including: Product Development Team Leader for NEUPOGEN(R); Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also a director of AMAG Pharmaceuticals, Inc.

Mr. Narachi received B.S. and M.A. degrees in Molecular Genetics from the University of California at Davis. He also received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
5. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
6. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. MRSA study suggests strategy shift needed to develop effective therapeutics
9. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
10. MPM Capital Leads Investment in Proteon Therapeutics
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... ... Unresponsive to Conventional Medical Treatments. , ... Boca Raton, FL (PRWEB) July 2, 2010 -- Amy, a 55 ... Under traditional drug treatment, which included five daily pills and injections, Amy,s condition only ...
... ... LA-540, an aspirator and liposuction system that is dependable and affordably-priced. , ... Louisville, KY (Vocus) July 2, ... DRE LA-540 , an affordable aspirator and liposuction system that features two positive ...
... ... It, Personal Notes, and the new book, Write the Right Words, answers the question of what ... ... I write?"--when a friend,s beloved pet dies; a favorite aunt wins that coveted prize; or a ...
... are up to twice as likely as other races ... nearly every common cancer type, the largest differences occur ... that black patients are not getting needed lifesaving treatments, ... of Michigan Comprehensive Cancer Center. Five-year survival rates ...
... ... its new upper extremity range, bebionic. Launched at the ISPO World congress in May, the ... approximately 9,000 Euros, or $11,000 USD. , ... (PRWeb UK) July 1, 2010 -- RSLSteeper have announced the pricing for the ...
... , THURSDAY, July 1 (HealthDay News) -- Scientists have grouped ... 77 percent accuracy whether or not a person will live ... probably could have predicted life span with even greater accuracy ... said Dr. Robert Marion, chief of genetics and development medicine ...
Cached Medicine News:Health News:New Approach to Rheumatoid Arthritis 2Health News:New Approach to Rheumatoid Arthritis 3Health News:DRE Introduces Economically-Priced Liposuction System 2Health News:DRE Introduces Economically-Priced Liposuction System 3Health News:Write the Right Words Answers What-to-Write Questions 2Health News:Why are blacks more likely to die from cancer diagnosis? 2Health News:RSLSteeper announces pricing for new bionic hand 2Health News:Scientists Spot Gene Variants That Predict Longevity 2Health News:Scientists Spot Gene Variants That Predict Longevity 3
(Date:10/20/2014)... 20, 2014  PneumRx, Inc. ( www.pneumrx.com ), a ... completion of enrollment in their RENEW Study, nearly 3 ... the FDA-approved IDE pivotal trial for the PneumRx RePneu ... It was anticipated that the study, which began enrolling ... until the end of 2014 to enroll 315 patients.  ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics announced ... the ability to collect human data at 30X depth, sufficient ... chip.  This new capability was established and demonstrated for the ... Irys TM System and will be rolled out ... BioNano will be showcasing this advancement at the American ...
Breaking Medicine Technology:PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... care and gastroenterology markets, today announced fourth quarter and full ... For the three months ended December 31, 2010, net revenue ... corresponding period in 2009. This quarterly revenue growth was largely ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... immediately. "I am pleased to have someone of ... Mark Guinan, Senior Vice President and Chief Financial Officer of ... will contribute to the solid financial leadership of our company ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... Spinal Fixation System is ... that provides an innovative ... It combines technical advances ... with a design philosophy ...
The CD Horizon Legacy Spinal System is part of the CD Horizon Spinal System designed for use in small stature patients. The posterior implants (hook and screws) are designed to fit patients in the ra...
... Spine System Evolution offers the latest technology ... of spinal pathologies including degenerative lumbar spine, ... is also intended for the treaent of ... the L5-S1 vertebra. Levels of pedicle screw ...
Medicine Products: